Review
doi: 10.1038/nrd2614.Nanoparticle therapeutics: an emerging treatment modality for cancer
Affiliations
- PMID:18758474
- DOI: 10.1038/nrd2614
Item in Clipboard
Review
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E Davis et al. Nat Rev Drug Discov.2008 Sep.
Display options
Format
Display options
Format
Abstract
Nanoparticles--particles in the size range 1-100 nm--are emerging as a class of therapeutics for cancer. Early clinical results suggest that nanoparticle therapeutics can show enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumours and active cellular uptake. Here, we highlight the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While large numbers of preclinical studies have been published, the emphasis here is placed on preclinical and clinical studies that are likely to affect clinical investigations and their implications for advancing the treatment of patients with cancer.
Similar articles
- Active targeting schemes for nanoparticle systems in cancer therapeutics.Byrne JD, Betancourt T, Brannon-Peppas L.Byrne JD, et al.Adv Drug Deliv Rev. 2008 Dec 14;60(15):1615-26. doi: 10.1016/j.addr.2008.08.005. Epub 2008 Sep 20.Adv Drug Deliv Rev. 2008.PMID:18840489Review.
- Nanoparticle technologies for cancer therapy.Alexis F, Pridgen EM, Langer R, Farokhzad OC.Alexis F, et al.Handb Exp Pharmacol. 2010;(197):55-86. doi: 10.1007/978-3-642-00477-3_2.Handb Exp Pharmacol. 2010.PMID:20217526Review.
- Nanoparticle and targeted systems for cancer therapy.Brannon-Peppas L, Blanchette JO.Brannon-Peppas L, et al.Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59. doi: 10.1016/j.addr.2004.02.014.Adv Drug Deliv Rev. 2004.PMID:15350294Review.
- The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo.Ng HL, Lu A, Lin G, Qin L, Yang Z.Ng HL, et al.Int J Mol Sci. 2014 Dec 24;16(1):230-55. doi: 10.3390/ijms16010230.Int J Mol Sci. 2014.PMID:25547490Free PMC article.Review.
- Composite nanoparticles take aim at cancer.Gil PR, Parak WJ.Gil PR, et al.ACS Nano. 2008 Nov 25;2(11):2200-5. doi: 10.1021/nn800716j.ACS Nano. 2008.PMID:19206383Review.
Cited by
- Dextran vesicular carriers for dual encapsulation of hydrophilic and hydrophobic molecules and delivery into cells.Pramod PS, Takamura K, Chaphekar S, Balasubramanian N, Jayakannan M.Pramod PS, et al.Biomacromolecules. 2012 Nov 12;13(11):3627-40. doi: 10.1021/bm301583s. Epub 2012 Oct 29.Biomacromolecules. 2012.PMID:23082727Free PMC article.
- Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab.Ma P, Zhang X, Ni L, Li J, Zhang F, Wang Z, Lian S, Sun K.Ma P, et al.Int J Nanomedicine. 2015 Mar 18;10:2173-90. doi: 10.2147/IJN.S77152. eCollection 2015.Int J Nanomedicine. 2015.PMID:25834432Free PMC article.
- α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug.Graf N, Bielenberg DR, Kolishetti N, Muus C, Banyard J, Farokhzad OC, Lippard SJ.Graf N, et al.ACS Nano. 2012 May 22;6(5):4530-9. doi: 10.1021/nn301148e. Epub 2012 May 14.ACS Nano. 2012.PMID:22584163Free PMC article.
- Enhanced preferential cytotoxicity through surface modification: synthesis, characterization and comparative in vitro evaluation of TritonX-100 modified and unmodified zinc oxide nanoparticles in human breast cancer cell (MDA-MB-231).Kc B, Paudel SN, Rayamajhi S, Karna D, Adhikari S, Shrestha BG, Bisht G.Kc B, et al.Chem Cent J. 2016 Apr 1;10:16. doi: 10.1186/s13065-016-0162-3. eCollection 2016.Chem Cent J. 2016.PMID:27042206Free PMC article.
- Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.Meng J, Agrahari V, Youm I.Meng J, et al.J Neuroimmune Pharmacol. 2017 Mar;12(1):84-98. doi: 10.1007/s11481-016-9698-1. Epub 2016 Jul 23.J Neuroimmune Pharmacol. 2017.PMID:27449494Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources